Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy

Joanna K L Wong1, Rashin Mohseni2, Amir Ali Hamidieh2

  • 1School of Medicine, Imperial College London, London, UK.

Trends in Biotechnology
|August 21, 2017
PubMed

Insights

Organic nanoparticle-based (ONP) gene therapy shows promise for cancer treatment. However, significant practical challenges hinder its clinical application, despite positive preclinical results.

Area of Science:

  • Oncology
  • Nanotechnology
  • Gene Therapy

Background:

  • Organic nanoparticle-based (ONP) gene therapy presents a novel approach for cancer treatment.
  • Promising in vitro and preclinical data suggest significant therapeutic potential.

Discussion:

  • Clinical translation of ONP gene therapy faces numerous practical barriers.
  • Hesitancy in clinical adoption stems from challenges in scalability, safety, and regulatory pathways.

Key Insights:

  • Understanding the specific hurdles is crucial for advancing ONP gene therapy.
  • Bridging the gap between preclinical success and clinical reality requires targeted solutions.

Outlook:

  • Overcoming current limitations is essential for realizing the full potential of ONP gene therapy in oncology.
  • Future research should focus on addressing practical challenges to facilitate clinical integration.